Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
43 hedge funds and large institutions have $187M invested in Telesis Bio, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 8 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
144% more capital invested
Capital invested by funds: $76.7M → $187M (+$110M)
0% more funds holding
Funds holding: 43 → 43 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.08M |
| 2 |
OAM
Ophir Asset Management
Sydney,
Australia
|
+$2.21M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$1.63M |
| 4 |
PVI
Pura Vida Investments
New York
|
+$1.55M |
| 5 |
BlackRock
New York
|
+$1.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.97M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.71M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$982K |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$723K |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$545K |
TBIO Hedge Fund Activity: Q4 2021 in Review
43 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q4 2021, worth a combined $187M — up 144% from $76.7M a quarter earlier.
Fund positioning in TBIO was balanced in Q4 2021: 8 funds opened new positions, 8 closed out, 20 added to existing stakes and 8 trimmed.
The largest buyer was Millennium Management, adding an estimated $5.08M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.97M sold.
- 43 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $187M of Telesis Bio, Inc. Common Stock stock for Q4 2021, up 144% quarter-over-quarter.
- 8 funds opened new Telesis Bio, Inc. Common Stock positions in Q4 2021 and 8 closed out, a net change of 0 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q4 2021 was Millennium Management, an estimated $5.08M added.
- The largest Telesis Bio, Inc. Common Stock seller in Q4 2021 was Armistice Capital, an estimated $5.97M sold.
Based on aggregated 13F filings for Q4 2021.